人工関節感染症(PJI)治療薬の世界市場:インサイト・疫学・市場予測

◆英語タイトル:Prosthetic Joint Infection (PJI) Market Insights, Epidemiology, and Market Forecast - 2030
◆商品コード:DELV20JU147
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2020年5月
◆ページ数:169
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後2営業日)
◆調査対象地域:アメリカ、ヨーロッパ、日本
◆販売価格オプション(消費税別)
Single User(147名様閲覧)USD6,950 ⇒換算¥729,750見積依頼/購入/質問フォーム
Three UserUSD10,425 ⇒換算¥1,094,625見積依頼/購入/質問フォーム
Site LicenseUSD13,900 ⇒換算¥1,459,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

DelveInsight’s ‘Prosthetic Joint Infection Market Insights, Epidemiology, and Market Forecast – 2030’ report deliver an in-depth understanding of the Prosthetic joint infection (PJI), historical and forecasted epidemiology as well as the Prosthetic joint infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Prosthetic joint infection market report provides current treatment practices, emerging drugs and their market share of the individual therapies, current and forecasted PJI symptoms market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Prosthetic joint infection (PJI) symptoms treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered
• The United States

• EU5 (Germany, France, Italy, Spain, and the United Kingdom)

• Japan

Study Period: 2017–2030

Prosthetic joint infection Disease Understanding and Treatment Algorithm
Prosthetic Joint Infection Overview

Prosthetic joint infection (PJI), also known as the peri-prosthetic infection, is defined as an infection involving the joint prosthesis and adjacent tissue. It is one of the significant complications and etiologies of implant failure after joint replacement and associated with a substantial financial burden on the healthcare system, and significant physical and psychological morbidity on patients.

The majority of PJIs occurring within one year of surgery are initiated through the introduction of microorganisms at the time of surgery, and this can occur through either direct contact or aerosolized contamination of the prosthesis or periprosthetic tissue. The most common observed microorganism responsible for PJI is S. aureus bacteremia. Along with this, Coagulase-negative staphylococci, Streptococcus species, Enterococcus species, and aerobic Gram-negative bacilli also play an essential role in the infection.

The clinical manifestations of PJI may include pain, swelling in joint or effusion, erythema or warmth around the joint, fever, drainage, or the presence of a sinus tract communicating with the arthroplasty and others. However, pain is observed as the most frequently reported clinical manifestation. The factors which are responsible for PJI are Diabetes mellitus, Rheumatoid arthritis, male gender, smoking, etc. The diagnosis of PJI continues to be a significant challenge in clinical practice.

Prosthetic joint infection (PJI) Diagnosis and Treatment
It covers the details of conventional and current medical therapies and diagnosis available in the Prosthetic joint infection (PJI) market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

The DelveInsight Prosthetic joint infection (PJI) market report gives a thorough understanding of PJI symptoms by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides PJI symptoms of treatment algorithms and treatment guidelines for PJI symptoms in the US, Europe, and Japan.

A combination of clinical findings, laboratory results from peripheral blood and synovial fluid, microbiological data, histological evaluation of periprosthetic tissue, intraoperative inspection, and, in some cases, radiographic results can help in the diagnosis of PJI. Twofold is the general approach to PJI diagnosis. First, it must be found whether the joint is infected; second if PJI is present; the causative microorganism(s) must be identified, and in many of the cases, its antimicrobial susceptibility must be determined.

Prosthetic joint infection (PJI) Epidemiology
The PJI symptoms epidemiology division provides insights about the historical and current patient pool, along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The diagnosed prevalent cases of Prosthetic joint infection (PJI) is increasing in 7MM during the study period, i.e. 2017-2030.
The disease epidemiology covered in the report provides historical as well as forecasted PJI symptoms epidemiology segmented as the Total prevalence of Arthroplasty, Total prevalence of PJI, Gender-Specific cases of PJI, Causative Microorganism-specific cases of PJI. The report includes the prevalent scenario of PJI symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Prosthetic joint infection (PJI) Epidemiology

The epidemiology segment also provides the Prosthetic joint infection (PJI) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The total prevalent population of PJI in 7MM countries was estimated to be 58,832 in 2017.

Prosthetic joint infection (PJI) Drug Chapters
The drug chapter segment of the Prosthetic joint infection (PJI) report encloses the detailed analysis of PJI marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Prosthetic joint infection (PJI) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Prosthetic joint infection (PJI) Emerging Drugs

Sodium Fusidate: Arrevus

Sodium Fusidate (Arrevus) is the only member of a unique class of antibiotics, called fusidanes, and has a mechanism of action that differs from any other antibiotic. It is active against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus strains (MRSA) and interferes with the function of elongation factor G (EF-G), leading to the inhibition of protein synthesis. The product has completed II/III studies for the treatment of PJI and has also received the Orphan designation. It has been approved in Europe but never been approved in the US. Therefore its approval will lead to a good market share in the US.

Products detail in the report.

Prosthetic joint infection (PJI) Market Outlook

The Prosthetic joint infection (PJI) market outlook of the report helps to build the detailed comprehension of the historical, current and forecasted Prosthetic joint infection (PJI) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Prosthetic joint infection (PJI) market trend of each marketed drug and late-stage pipeline therapy by assessing their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Prosthetic joint infection (PJI) market in 7MM is expected to grow in the study period 2017 – 2030.

The current therapeutic landscape in the 7MM of PJI usually requires combined medical-surgical strategies, including open or arthroscopic debridement without removal of the prosthesis, resection of the prosthesis with or without reimplantation either at the time of removal or delayed by weeks to months. Further arthrodesis, amputation, or antimicrobial suppression without surgery are also recommended.

Antimicrobial therapy should be pathogen directed and guided by the results of antimicrobial susceptibility testing, where applicable. General principles for antimicrobial treatment apply, with priority given to the least toxic, most efficacious, narrow-spectrum antimicrobial regimen.

The generally used antibiotics are Cefazolin, Rifampin, Ciprofloxacin, Vancomycin, Penicillin, Ceftriaxone, Ampicillin, Gentamicin, Clindamycin, and others. These antibiotics may be used as monotherapy or combination therapy depending on the type of microorganisms.

Key Findings

This section includes a glimpse of the Prosthetic joint infection market in 7MM. PJI market size in the seven major markets was found to be USD 57.69 million in 2017.

The United States Market Outlook

This section provides the total Prosthetic joint infection (PJI) market size and market size by therapies in the United States.
The United States accounts for the highest market size of PJI in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

EU-5 Countries: Market Outlook

The total Prosthetic joint infection (PJI) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Given the heterogeneous nature of prosthetic joint infections, there are no large randomized control trials to guide recommendations. Surgical strategies differ significantly worldwide; exchange procedures are the popular treatment modality in Northern America, whereas debridement and retention are more commonly performed in Europe. One-stage or direct arthroplasty exchange—preferred more in Europe; Two-stage arthroplasty exchange— preferred more in the US.

Japan Market Outlook

The total Prosthetic joint infection (PJI) market Size and market Size by therapies in Japan are also mentioned.

Prosthetic joint infection (PJI) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2017–2030. The analysis covers Prosthetic joint infection (PJI) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Prosthetic joint infection (PJI) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Prosthetic joint infection (PJI) key players involved in developing targeted therapeutics.

Major players include Arrevus, TenNor Therapeutics, Peptilogics and others.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing and patent details for Prosthetic joint infection (PJI) emerging therapies.

Reimbursement Scenario in PJI

Approaching reimbursement can have a positive impact both during the late stages of product development and well after product launch. In the report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business & price strategy.

The government is the primary payer for the majority of PJI cases, through Medicare spending. In addition to improving patient outcomes, prevention of PJI may save costs to the Medicare program. Several reimbursements and other strategies are on the horizon that will impact provider compensation for physicians and hospitals.

KOL- Views

To keep up with current market trends, we take KOLs and SME’s opinion working in Prosthetic joint infection (PJI) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Prosthetic joint infection (PJI) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive & Market Intelligence analysis of the Prosthetic joint infection (PJI) Market by using various Competitive Intelligence tools that includes – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
The report covers the descriptive overview of PJI, explaining its causes, signs and symptoms, pathophysiology and currently available therapies
Comprehensive insight has been provided into the Prosthetic joint infection (PJI) epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Prosthetic joint infection (PJI) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of Prosthetic joint infection (PJI) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Prosthetic joint infection (PJI) market

Report Highlights
In the coming years, Prosthetic joint infection (PJI) market is set to change due to the rising awareness of the disease, and Favorable Environment for New Anti-infective Modalities; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
The companies and academics are working to assess challenges and seek opportunities that could influence Prosthetic joint infection (PJI) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
Major players are involved in developing therapies for PJI. Launch of emerging therapies will significantly impact the Prosthetic joint infection (PJI) market
Molecular biology techniques offer the possibility to formulate rapid microbiological identification in the treatment of PJIs
Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Prosthetic joint infection (PJI) Report Insights
Patient Population
Therapeutic Approaches
Prosthetic joint infection (PJI) Pipeline Analysis
Prosthetic joint infection (PJI) Market Size and Trends
Market Opportunities
Impact of upcoming Therapies

Prosthetic joint infection (PJI) Report Key Strengths
11 Years Forecast
7MM Coverage
Prosthetic joint infection (PJI) Epidemiology Segmentation
Key Cross Competition
Highly Analyzed Market
Drugs Uptake

Prosthetic joint infection (PJI) Report Assessment
Current Treatment Practices
Unmet Needs
Pipeline Product Profiles
Market Attractiveness
Market Drivers and Barriers

Key Questions
Market Insights:

What were the Prosthetic joint infection (PJI) Market share (%) distribution in 2017 and how it would look like in 2030?
What is the trend of arthroplasty cases for joint replacement in the coming years?
What would be the Prosthetic joint infection (PJI) total market Size as well as market Size by therapies across the 7MM during the forecast period (2017–2030)?
What are the key findings pertaining to the market across 7MM and which country will have the largest Prosthetic joint infection (PJI)market Size during the forecast period (2017–2030)?
At what CAGR, the Prosthetic joint infection (PJI) market is expected to grow in 7MM during the forecast period (2017–2030)?
What would be the Prosthetic joint infection (PJI) market outlook across the 7MM during the forecast period (2017–2030)?
What would be the Prosthetic joint infection (PJI) market growth till 2030, and what will be the resultant market Size in the year 2030?
How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

What is the disease risk, burden and unmet needs of the PJI?
What is the historical Prosthetic joint infection (PJI) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan?
What would be the forecasted patient pool of Prosthetic joint infection (PJI) in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan?
What will be the growth opportunities in the 7MM with respect to the patient population pertaining to PJI?
Out of all 7MM countries, which country would have the highest prevalent population of Prosthetic joint infection (PJI) during the forecast period (2017–2030)?
At what CAGR the population is expected to grow in 7MM during the forecast period (2017–2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
What are the current options for the treatment of Prosthetic joint infection (PJI) along with the approved therapy?
What are the current treatment guidelines for the treatment of Prosthetic joint infection (PJI) in the USA, Europe, and Japan?
What are the Prosthetic joint infection (PJI) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
How many companies are developing therapies for the treatment of PJI?
How many therapies are developed by each company for the treatment of PJI?
What is going to be the scenario for PJI treatment for gram-negative pathogens? What emerging therapies are targeting gram-negative pathogens?
How many emerging therapies are in the mid-stage and late stages of development for the treatment of PJI?
What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Prosthetic joint infection (PJI) therapies?
What are the new novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Prosthetic joint infection (PJI) and their status?
What are the key designations that have been granted for the emerging therapies for PJI?
What are the global historical and forecasted market of PJI?

Reasons to buy
The report will help in developing business strategies by understanding trends shaping and driving the Prosthetic joint infection (PJI) market
To understand the future market competition in the Prosthetic joint infection (PJI) market and Insightful review of the key market drivers and barriers
Organize sales and marketing efforts by identifying the best opportunities for Prosthetic joint infection (PJI) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
Organize sales and marketing efforts by identifying the best opportunities for Prosthetic joint infection (PJI) market
To understand the future market competition in the Prosthetic joint infection (PJI) market

【レポートの目次】

1. Key Insights

2. Organizations

3. Executive summary

4. Epidemiology and Market Methodology

5. Prosthetic joint infection (PJI): Market Overview at a Glance

5.1. Total Market Share (%) Distribution of Prosthetic joint infection (PJI) in 2017

5.2. Total Market Share (%) Distribution of Prosthetic joint infection (PJI) in 2030

6. Overview

6.1. Introduction

6.2. Signs and Symptoms

6.3. Risk Factors

6.4. Pathogenesis

6.5. Causative Microorganisms

6.6. Classification

6.7. Diagnosis

6.7.1. Diagnostic Guidelines

6.7.2. Biologics and Biomarkers in the Treatment and Diagnosis of Prosthetic Joint Infection

7. Epidemiology and Patient Population

7.1. Key Findings

7.2. Total cases of Prosthetic joint infection (PJI) in 7MM

8. Country Wise-Epidemiology of Prosthetic Joint Infection

8.1. Country Wise-Epidemiology of Prosthetic Joint Infection

8.2. United States

8.2.1. Assumptions and Rationale

8.2.2. Total number of Arthroplasty in the United States

8.2.3. Total Prosthetic joint infection (PJI) cases in the US

8.2.4. Gender-Specific cases of Prosthetic Joint Infection in the United States

8.2.5. Causative Microorganism-specific cases of Prosthetic joint infection (PJI) in the United States

8.3. EU5 Countries

8.4. Germany

8.4.1. Assumptions and Rationale

8.4.2. Total number of Arthroplasty in Germany

8.4.3. Total Prosthetic joint infection (PJI) cases in Germany

8.4.4. Gender-Specific cases of Prosthetic Joint Infection in Germany

8.4.5. Causative Microorganism-specific cases of Prosthetic joint infection (PJI) in Germany

8.5. France

8.5.1. Assumptions and Rationale

8.5.2. Total number of Arthroplasty in France

8.5.3. Total Prosthetic joint infection (PJI) cases in France

8.5.4. Gender-Specific cases of Prosthetic Joint Infection in France

8.5.5. Causative Microorganism-specific cases of Prosthetic joint infection (PJI) France

8.6. Italy

8.6.1. Assumptions and Rationale

8.6.2. Total number of Arthroplasty in Italy

8.6.3. Total Prosthetic joint infection (PJI) cases in Italy

8.6.4. Gender-Specific cases of Prosthetic Joint Infection in Italy

8.6.5. Causative Microorganism-specific cases of Prosthetic joint infection (PJI) in Italy

8.7. Spain

8.7.1. Assumptions and Rationale

8.7.2. Total Number of Arthroplasty in Spain

8.7.3. Total Prosthetic joint infection (PJI) cases in Spain

8.7.4. Gender-Specific cases of Prosthetic Joint Infection in Spain

8.7.5. Causative Microorganism-specific cases of Prosthetic joint infection (PJI) Spain

8.8. UK

8.8.1. Assumptions and Rationale

8.8.2. Total Number of Arthroplasty in the United Kingdom

8.8.3. Total Prosthetic joint infection (PJI) cases in the United Kingdom

8.8.4. Gender-Specific cases of Prosthetic Joint Infection in the United Kingdom

8.8.5. Causative Microorganism-specific cases of Prosthetic joint infection (PJI) in the United Kingdom

8.9. Japan

8.9.1. Assumptions and Rationale

8.9.2. Total number of Arthroplasty in Japan

8.9.3. Total Prosthetic joint infection (PJI) cases in Japan

8.9.4. Gender-Specific cases of Prosthetic Joint Infection in Japan

8.9.5. Causative Microorganism-specific cases of Prosthetic joint infection (PJI) in Japan

9. Treatment

9.1. Treatment guidelines

10. Unmet Needs

11. Emerging Therapies

11.1. Key Cross Competition

11.2. Sodium Fusidate: Arrevus

11.2.1. Drug Description

11.2.2. Other developmental activities

11.2.3. Clinical Development

11.2.4. Safety and Efficacy

11.2.5. Product Profile

11.3. TNP-2092: TenNor Therapeutics

11.3.1. Drug Description

11.3.2. Other developmental activities

11.3.3. Safety and Efficacy

11.3.4. Product Profile

11.4. PLG0206: Peptilogics

11.4.1. Drug Description

11.4.2. Other developmental activities

11.4.3. Clinical Development

11.4.4. Safety and Efficacy

11.4.5. Product Profile

11.5. Other Potential Therapies

11.5.1. Exebacase: ContraFect

11.5.2. Vancomycin hydrochloride and tobramycin sulfate: Joint Purification Systems

12. Prosthetic Joint Infection (PJI): 7 Major Market Analysis

12.1. Key Findings

12.2. Market Size of Prosthetic Joint Infection in 7MM

13. Seven Major Market Outlook

13.1. United States Market Size

13.1.1. The total market size of Prosthetic Joint Infection in the United States

13.1.2. The total market size of Prosthetic Joint Infection by Therapies in the United States

13.2. Germany

13.2.1. The total market size of Prosthetic Joint Infection in Germany

13.2.2. The total market size of Prosthetic Joint Infection by Therapies in Germany

13.3. France

13.3.1. The total market size of Prosthetic Joint Infection in France

13.3.2. The total Market size of Prosthetic Joint Infection by Therapies in France

13.4. Italy

13.4.1. The total market size of Prosthetic Joint Infection in Italy

13.4.2. The total Market size of Prosthetic Joint Infection by Therapies in Italy

13.5. Spain

13.5.1. Total Market Size of Prosthetic Joint Infection in Spain

13.5.2. The total market size of Prosthetic Joint Infection by Therapies in Spain

13.6. United Kingdom

13.6.1. The total market size of Prosthetic Joint Infection in the United Kingdom

13.6.2. The total market size of Prosthetic Joint Infection by Therapies in the UK

13.7. Japan

13.7.1. The total market size of Prosthetic Joint Infection in Japan

13.7.2. The total market size of Prosthetic Joint Infection by Therapies in Japan

14. Market Drivers

15. Market Barriers

16. Reimbursement policies

17. SWOT

18. Case Study

18.1. A Case Report of Prosthetic Joint Infection due to Candida parapsilosis in the UK

18.2. A Case Report of Prosthetic joint infection: an extremely rare complication of intravesicular BCG therapy

19. KOL Views

20. Bibliography

21. Appendix

21.1. Report Methodology

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

Table 1: Key organizations of PJI

Table 2: Classifications of prosthetic joint infections (PJI)

Table 3: Prosthetic joint infections: clinical management, diagnosis, and treatment

Table 4: Proposed definitions for prosthetic joint infection

Table 5: Total cases of Prosthetic joint infection (PJI) in 7MM (2017–2030)

Table 6: Total number of Arthroplasty in the United States (2017–2030)

Table 7: Total Prosthetic Joint Infection cases in the US (2017–2030)

Table 8: Gender-specific cases of Prosthetic Joint Infection in the US (2017–2030)

Table 9: Causative Microorganism-specific cases of Prosthetic Joint Infection in the US (2017–2030)

Table 10: Total number of Arthroplasty in Germany (2017–2030)

Table 11: Total Prosthetic Joint Infection cases in Germany (2017–2030)

Table 12: Gender-specific cases of Prosthetic Joint Infection in Germany (2017–2030)

Table 13: Causative Microorganism-specific cases of Prosthetic Joint Infection in Germany (2017–2030)

Table 14: Total number of Arthroplasty in France (2017–2030)

Table 15: Total Prosthetic Joint Infection cases in France (2017–2030)

Table 16: Gender-specific cases of Prosthetic Joint Infection in France (2017–2030)

Table 17: Causative Microorganism-specific cases of Prosthetic Joint Infection in France (2017–2030)

Table 18: Total number of Arthroplasty in Italy (2017–2030)

Table 19: Total Prosthetic Joint Infection cases in Italy (2017–2030)

Table 20: Gender-specific cases of Prosthetic Joint Infection in Italy (2017–2030)

Table 21: Causative Microorganism-specific cases of Prosthetic Joint Infection in Italy (2017–2030)

Table 22: Total Number of Arthroplasty in Spain (2017–2030)

Table 23: Total Prosthetic Joint Infection cases in Germany (2017–2030)

Table 24: Gender-specific cases of Prosthetic Joint Infection in Spain (2017–2030)

Table 25: Causative Microorganism-specific cases of Prosthetic Joint Infection in Spain (2017–2030)

Table 26: Total Number of Arthroplasty in the United Kingdom (2017–2030)

Table 27: Total Prosthetic Joint Infection cases in the UK (2017–2030)

Table 28: Gender-specific cases of Prosthetic Joint Infection in the UK (2017–2030)

Table 29: Causative Microorganism-specific cases of Prosthetic Joint Infection in UK (2017–2030)

Table 30: Total number of Arthroplasty in Japan (2017–2030)

Table 31: Total Prosthetic Joint Infection cases in Japan (2017–2030)

Table 32: Gender-specific cases of Prosthetic Joint Infection in Japan (2017–2030)

Table 33: Causative Microorganism-specific cases of Prosthetic Joint Infection in Japan (2017–2030)

Table 34: Suggested antimicrobials for treatment of PJI

Table 35: Key cross of emerging drugs

Table 36: Sodium Fusidate, Clinical Trial Description, 2020

Table 37: PLG0206, Clinical Trial Description, 2020

Table 38: Vancomycin hydrochloride and tobramycin sulfate, Clinical Trial Description, 2020

Table 39: Market Size of Prosthetic Joint Infection in 7MM in USD Million (2017–2030)

Table 40: US Market Size of Prosthetic Joint Infection in USD Million (2017–2030)

Table 41: US Market Size of Prosthetic Joint Infection in USD Million (2017–2030)

Table 42: Market Size of Prosthetic Joint Infection in Germany, USD Millions (2017–2030)

Table 43: Germany Market Size of Prosthetic Joint Infection in USD Million (2017–2030)

Table 44: Market Size of Prosthetic Joint Infection associated in France, USD Millions (2017–2030)

Table 45: France Market Size of Prosthetic Joint Infection in USD Million (2017–2030)

Table 46: Market Size of Prosthetic Joint Infection in Italy, USD Millions (2017–2030)

Table 47: Italy Market Size of Prosthetic Joint Infection in USD Million (2017–2030)

Table 48: Market Size of Prosthetic Joint Infection in Spain, USD Millions (2017–2030)

Table 49: Spain Market Size of Prosthetic Joint Infection in USD Million (2017–2030)

Table 50: Market Size of Prosthetic Joint Infection in the UK, USD Millions (2017–2030)

Table 51: UK Market Size of Prosthetic Joint Infection in USD Million (2017–2030)

Table 52: Market Size of Prosthetic Joint Infection in Japan, USD Millions (2017–2030)

Table 53:Japan Market Size of Prosthetic Joint Infection in USD Million (2017–2030)



List of Figures

Figure 1: Epidemiology and Market Methodology

Figure 2: Signs and Symptoms for PJI

Figure 3: Risk factors for PJI

Figure 4: Pathogen that causes septic arthritis and prosthetic joint Infection

Figure 5: Preoperative and intraoperative diagnosis of prosthetic joint infection

Figure 6: Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC)

Figure 7: Total cases of Prosthetic joint infection (PJI) in 7MM (2017–2030)

Figure 8: Total number of Arthroplasty in the United States (2017–2030)

Figure 9: Total Prosthetic Joint Infection cases in the US (2017–2030)

Figure 10: Gender-Specific cases of Prosthetic Joint Infection in the US (2017–2030)

Figure 11: Causative Microorganism-specific cases of Prosthetic Joint Infection in the US (2017–2030)

Figure 12: Total number of Arthroplasty in Germany (2017–2030)

Figure 13: Total Prosthetic Joint Infection cases in Germany (2017–2030)

Figure 14: Gender-Specific cases of Prosthetic Joint Infection in Germany (2017–2030)

Figure 15: Causative Microorganism-specific cases of Prosthetic Joint Infection in Germany (2017–2030)

Figure 16: Total number of Arthroplasty in France (2017–2030)

Figure 17: Total Prosthetic Joint Infection cases in France (2017–2030)

Figure 18: Gender-Specific cases of Prosthetic Joint Infection in France (2017–2030)

Figure 19: Causative Microorganism-specific cases of Prosthetic Joint Infection in France (2017–2030)

Figure 20: Total number of Arthroplasty in Italy (2017–2030)

Figure 21: Total Prosthetic Joint Infection cases in Italy (2017–2030)

Figure 22: Gender-Specific cases of Prosthetic Joint Infection in Italy (2017–2030)

Figure 23: Causative Microorganism-specific cases of Prosthetic Joint Infection in Italy (2017–2030)

Figure 24: Total Number of Arthroplasty in Spain (2017–2030)

Figure 25: Total Prosthetic Joint Infection cases in Germany (2017–2030)

Figure 26: Gender-Specific cases of Prosthetic Joint Infection in Spain (2017–2030)

Figure 27: Causative Microorganism-specific cases of Prosthetic Joint Infection in Spain (2017–2030)

Figure 28: Total Number of Arthroplasty in the United Kingdom (2017–2030)

Figure 29: Total Prosthetic Joint Infection cases in the UK (2017–2030)

Figure 30: Gender-Specific cases of Prosthetic Joint Infection in the UK (2017–2030)

Figure 31: Causative Microorganism-specific cases of Prosthetic Joint Infection in the UK (2017–2030)

Figure 32: Total number of Arthroplasty in Japan (2017–2030)

Figure 33: Total Prosthetic Joint Infection cases in Japan (2017–2030)

Figure 34: Gender-Specific cases of Prosthetic Joint Infection in Japan (2017–2030)

Figure 35: Causative Microorganism-specific cases of Prosthetic Joint Infection in Japan (2017–2030)

Figure 36: Surgical Procedures of PJIs

Figure 37: Management of Prosthetic Joint infection

Figure 38: Treatment Algorithm

Figure 39: Unmet Needs

Figure 40: Market Size of Prosthetic Joint Infection in USD Million (2017–2030)

Figure 41: Market Size of Prosthetic Joint Infection in the US, USD Millions (2017–2030)

Figure 42: Market Size of Prosthetic Joint Infection in the US by therapies, USD Millions (2017–2030)

Figure 43: Market Size of Prosthetic Joint Infection in Germany, USD Millions (2017–2030)

Figure 44: Market Size of Prosthetic Joint Infection in Germany by therapies, USD Millions (2017–2030)

Figure 45: Market Size of Prosthetic Joint Infection in France, USD Millions (2017–2030)

Figure 46: Market Size of Prosthetic Joint Infection in France by therapies, USD Millions (2017–2030)

Figure 47: Market Size of Prosthetic Joint Infection in Italy, USD Millions (2017–2030)

Figure 48: Market Size of Prosthetic Joint Infection in Italy by therapies, USD Millions (2017–2030)

Figure 49: Market Size of Prosthetic Joint Infection in Spain, USD Millions (2017–2030)

Figure 50: Market Size of Prosthetic Joint Infection in Spain by therapies, USD Millions (2017–2030)

Figure 51: Market Size of Prosthetic Joint Infection in the UK, USD Millions (2017–2030)

Figure 52: Market Size of Prosthetic Joint Infection in the UK by therapies, USD Millions (2017–2030)

Figure 53: Market Size of Prosthetic Joint Infection in Japan, USD Millions (2017–2030)

Figure 54: Market Size of Prosthetic Joint Infection in Japan by therapies, USD Millions (2017–2030)

Figure 55: Market Drivers

Figure 56:Market Barriers

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[人工関節感染症(PJI)治療薬の世界市場:インサイト・疫学・市場予測]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆